Latest Healthcare News

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Terra Critical Minerals (ASX – T92) has identified notable bismuth mineralisation alongside tungsten, molybdenum, and tin at its Glen Eden Project in NSW, adding a valuable critical mineral to its portfolio amid rising global demand.

Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, has landed three new cloud-based contracts worth a combined minimum of A$29 million, reinforcing its strong foothold across diverse healthcare segments.

Echo IQ has completed a pivotal clinical validation of its EchoSolv HF software at the Mayo Clinic, achieving outstanding accuracy ahead of its FDA submission. This milestone sets the stage for potential US market entry into a $60 billion heart failure diagnostics sector.

Ryman Healthcare has completed a full refinancing of its $2 billion syndicated loan facilities, extending the average maturity to five years and enhancing funding flexibility. The move aligns with the company’s disciplined growth strategy and sets the stage for future capital management decisions.

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

Oceania Healthcare Limited reported a robust 1HY26 performance, marked by increased sales volumes, improved care profitability, and disciplined capital management. The company’s strategic focus on sales, operational excellence, and debt reduction sets a solid foundation for sustainable growth.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Oceania Healthcare has posted a strong half-year turnaround with improved sales, cost savings, and reduced gearing, setting the stage for renewed growth and operational strength.

Oceania Healthcare reported a slight dip in revenue but impressive gains in profitability for the first half of 2025, highlighting operational resilience amid a challenging environment.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.